^
    Back
    Association details:
    Biomarker:AR positive
    Cancer:Prostate Cancer
    Drug:pruxelutamide (GT0918) (Androgen receptor antagonist, TMPRSS2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ADA 2020
    Title:

    MP16-15: Metabolomic profiling to evaluate the pharmacodynamic of Proxalutamide, a novel androgen receptor antagonist

    Published date:
    05/15/2020
    Excerpt:
    Cell viability assay indicated that proxalutamide showed potent anti-proliferative effects on AR-positive cells but weak on AR-negative cells.